SPONSOR
Shengjing Hospital
Total Trials
3
Recruiting
3
Phases
Phase 4
Conditions studied: Breast Cancer
Shengjing Hospital is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Breast Cancer.
The trial portfolio spans Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shengjing Hospital
How many clinical trials has Shengjing Hospital sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Shengjing Hospital, of which 3 are actively recruiting participants. These trials cover conditions including Breast Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shengjing Hospital research focus on?
Shengjing Hospital clinical trials span Breast Cancer. The research pipeline includes Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shengjing Hospital clinical trial?
To participate in a Shengjing Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shengjing Hospital trials with current recruitment status updated daily.
Clinical Trials by Shengjing Hospital
NCT04476485
Recruiting
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
Breast Cancer
NCT05346510
Recruiting
Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer
Breast Cancer
NCT04136782 Phase 4
Recruiting
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology